Please wait while the formulary information is being retrieved.
TADALAFIL (tadalafil)
- Erectile dysfunction
- Pulmonary arterial hypertension
- Benign prostatic hyperplasia with lower urinary tract sx
- Tadalafil Tablet
- Tadalafil (pulmonary Hypertension) Tablet
- Tadalafil (antihypertensive) Tablet
- Cialis Tablet
- Alyq Tablet
- Adcirca Tablet
- By Indication
10 mg tablet
- 1 tablet (10 mg) by oral route once daily
2.5 mg tablet
- 1 tablet (2.5 mg) by oral route once daily
20 mg tablet
- 1 tablet (20 mg) by oral route once daily
5 mg tablet
- 1 tablet (5 mg) by oral route once daily
tadalafil 20 mg tablet (pulmonary hypertension)
- 2 tablets (40 mg) by oral route once daily
20 mg tablet (pulmonary hypertension)
- 2 tablets (40 mg) by oral route once daily
10 mg tablet
- 1 tablet (10 mg) by oral route once daily
2.5 mg tablet
- 1 tablet (2.5 mg) by oral route once daily
20 mg tablet
- 1 tablet (20 mg) by oral route once daily
5 mg tablet
- 1 tablet (5 mg) by oral route once daily
20 mg tablet
- 2 tablets (40 mg) by oral route once daily
20 mg tablet
- 2 tablets (40 mg) by oral route once daily
Benign prostatic hyperplasia with lower urinary tract sx
- 1 tablet (5 mg) by oral route once daily at approximately the same time each day
- 2 tablets (5 mg) by oral route once daily at approximately the same time each day
Erectile dysfunction
- 2 tablets (5 mg) by oral route once daily
- 1 tablet (5 mg) by oral route once daily
- 1 tablet (5 mg) by oral route once daily at approximately the same time each day
- 2 tablets (5 mg) by oral route once daily at approximately the same time each day
- 1 tablet (5 mg) by oral route as needed approximately 1 hour before sexual activity
- 2 tablets (10 mg) by oral route as needed approximately 1 hour before sexual activity
- 1 tablet (10 mg) by oral route as needed approximately 1 hour before sexual activity
- 2 tablets (10 mg) by oral route once daily
- 1 tablet (10 mg) by oral route once daily
- 2 tablets (20 mg) by oral route once daily
- 1 tablet (20 mg) by oral route once daily
- 2 tablets (20 mg) by oral route as needed approximately 1 hour before sexual activity
- 1 tablet (20 mg) by oral route as needed approximately 1 hour before sexual activity
- 1 tablet (2.5 mg) by oral route once daily
Pulmonary arterial hypertension
- 1 tablet (20 mg) by oral route once daily
- 2 tablets (40 mg) by oral route once daily
- Adempas
- Bidil
- boceprevir
- Dilatrate-sr
- Imdur
- Incivek
- Isochron
- Isoditrate
- isosorbide dinitrate
- isosorbide mononitrate
- isosorbide-hydralazine
- Minitran
- Nithiodote
- Nitro-bid
- Nitro-dur
- Nitro-time
- nitroglycerin
- nitroglycerin in 5 % dextrose
- Nitrolingual
- Nitromist
- Nitropress
- nitroprusside
- Nitrostat
- riociguat
- sodium nitrite
- sodium nitrite-sod thiosulfate
- telaprevir
- Victrelis
Contraindicated
- None
Severe
Moderate
- alfuzosin
- amoxicil-clarithromy-lansopraz
- atazanavir
- Biaxin
- Biaxin Xl
- Biaxin Xl Pak
- Cardura
- Cardura Xl
- clarithromycin
- Crixivan
- Dibenzyline
- doxazosin
- dutasteride-tamsulosin
- elvitegr-cobicist-emtric-tenof
- Flomax
- fosamprenavir
- indinavir
- itraconazole
- Jalyn
- Kaletra
- Ketek
- ketoconazole
- Lexiva
- lopinavir-ritonavir
- Minipress
- nefazodone
- nelfinavir
- Norvir
- Norvir Soft Gelatin
- Omeclamox-pak
- omeprazole-clarith-amoxicillin
- Onmel
- phenoxybenzamine
- phentolamine
- prazosin
- Prevpac
- Reyataz
- ritonavir
- Sporanox
- Sporanox Pulsepak
- Stribild
- tamsulosin
- telithromycin
- terazosin
- Uroxatral
- Viracept
- Anterior ischemic optic neuropathy
Contraindicated
- Alcohol intoxication
- Aortic valve stenosis
- Cerebrovascular accident
- Chronic heart failure
- Disease of liver
- Fibrosis of corpus cavernosum
- Hypertrophic cardiomyopathy
- Hypotension
- Life-threatening cardiac arrhythmias
- Penile angulation
- Peptic ulcer
- Peyronie's disease
- Pigmentary retinopathy
- Renal disease with mild to moderate impairment
- Restrictive cardiomyopathy
- Severe renal impairment
- Severe uncontrolled hypertension
- Unstable angina pectoris
Severe
Moderate
- Hearing loss
- Increased risk of bleeding
- Increased risk of bleeding due to coagulation disorder
- Leukemia
- Multiple myeloma
- Seizure disorder
- Sickle cell disease
TADALAFIL (tadalafil)
- Erectile dysfunction
- Pulmonary arterial hypertension
- Benign prostatic hyperplasia with lower urinary tract sx
- None
- Headache disorder
More Frequent
Severe
Less Severe
- None
- Acute abdominal pain
- Back pain
- Cough
- Diarrhea
- Dyspepsia
- Flushing
- Gastroesophageal reflux disease
- Limb pain
- Myalgias
- Nasal congestion
- Nausea
- Pharyngitis
- Upper respiratory infection
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Acute myocardial infarction
- Angina
- Anterior ischemic optic neuropathy
- Blurred vision
- Cerebrovascular accident
- Chest pain
- Conjunctivitis
- Dysphagia
- Dyspnea
- Esophagitis
- Exfoliative dermatitis
- Facial edema
- Hearing loss
- Hypertension
- Hypotension
- Kidney disease with reduction in GFR
- Orthostatic hypotension
- Palpitations
- Priapism
- Rectal bleeding
- Retinal vascular occlusion
- Seizure disorder
- Stevens-johnson syndrome
- Syncope
- Tachycardia
- Vision loss
- Visual field defect
Less Severe
- Acquired chromatopsia
- Arthralgias
- Conjunctival hyperemia
- Dizziness
- Drowsy
- Epistaxis
- Eye tearing
- Eyelid edema
- Fatigue
- Frequent erections
- Gastritis
- General weakness
- Hyperhidrosis
- Hypesthesia
- Insomnia
- Loose stools
- Migraine
- Neck pain
- Ocular pain
- Pain
- Paresthesia
- Peripheral edema
- Pruritus of skin
- Skin rash
- Tinnitus
- Transient global amnesia
- Urticaria
- Vertigo
- Visual changes
- Vomiting
- Xerostomia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Tadalafil
No efficacy demonstrated in trials of Duchenne muscular dystrophy. Not indicated in pediatrics.
- 1 Day – 18 Years
- No efficacy demonstrated in trials of Duchenne muscular dystrophy. Not indicated in pediatrics.
Tadalafil
- Severity Level:
2
- Additional Notes: Insufficient human data available
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Tadalafil
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Tadalafil
Hepatic-Use caution with hepatic impairment. Renal-Adjust dose for moderate to severe renal impairment.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | Y | Y | Y | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Benign prostatic hyperplasia with lower urinary tract sx | |
| N40.1 | Benign prostatic hyperplasia with lower urinary tract symptoms |
| Erectile dysfunction | |
| F52.21 | Male erectile disorder |
| N52 | Male erectile dysfunction |
| N52.0 | Vasculogenic erectile dysfunction |
| N52.01 | Erectile dysfunction due to arterial insufficiency |
| N52.02 | Corporo-venous occlusive erectile dysfunction |
| N52.03 | Combined arterial insufficiency and corporo-venous occlusive erectile dysfunction |
| N52.1 | Erectile dysfunction due to diseases classified elsewhere |
| N52.2 | Drug-induced erectile dysfunction |
| N52.3 | Postprocedural erectile dysfunction |
| N52.31 | Erectile dysfunction following radical prostatectomy |
| N52.32 | Erectile dysfunction following radical cystectomy |
| N52.33 | Erectile dysfunction following urethral surgery |
| N52.34 | Erectile dysfunction following simple prostatectomy |
| N52.35 | Erectile dysfunction following radiation therapy |
| N52.36 | Erectile dysfunction following interstitial seed therapy |
| N52.37 | Erectile dysfunction following prostate ablative therapy |
| N52.39 | Other and unspecified postprocedural erectile dysfunction |
| N52.8 | Other male erectile dysfunction |
| N52.9 | Male erectile dysfunction, unspecified |
| Pulmonary arterial hypertension | |
| I27.0 | Primary pulmonary hypertension |
| I27.21 | Secondary pulmonary arterial hypertension |
| 0-9 | A-Z |
|---|---|
| F52.21 | Male erectile disorder |
| I27.0 | Primary pulmonary hypertension |
| I27.21 | Secondary pulmonary arterial hypertension |
| N40.1 | Benign prostatic hyperplasia with lower urinary tract symptoms |
| N52 | Male erectile dysfunction |
| N52.0 | Vasculogenic erectile dysfunction |
| N52.01 | Erectile dysfunction due to arterial insufficiency |
| N52.02 | Corporo-venous occlusive erectile dysfunction |
| N52.03 | Combined arterial insufficiency and corporo-venous occlusive erectile dysfunction |
| N52.1 | Erectile dysfunction due to diseases classified elsewhere |
| N52.2 | Drug-induced erectile dysfunction |
| N52.3 | Postprocedural erectile dysfunction |
| N52.31 | Erectile dysfunction following radical prostatectomy |
| N52.32 | Erectile dysfunction following radical cystectomy |
| N52.33 | Erectile dysfunction following urethral surgery |
| N52.34 | Erectile dysfunction following simple prostatectomy |
| N52.35 | Erectile dysfunction following radiation therapy |
| N52.36 | Erectile dysfunction following interstitial seed therapy |
| N52.37 | Erectile dysfunction following prostate ablative therapy |
| N52.39 | Other and unspecified postprocedural erectile dysfunction |
| N52.8 | Other male erectile dysfunction |
| N52.9 | Male erectile dysfunction, unspecified |
Formulary Reference Tool